Acquisition Bolsters Aspire’s Strategic Portfolio

Acquisition Bolsters Aspire’s Strategic Portfolio

Petersfield, Hampshire, 8^th May 2025, Aspire Pharma Limited, a rapidly growing UK-based specialty niche generics business, announces the bolstering of its product portfolio through the purchase of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

The distribution rights acquisition is for products connected with the treatment of bacterial infections, including injectable and intravenous antibiotics, as well as a medicine associated with the treatment of acute myocardial infarction (MI) and deep vein thrombosis (DVT).

The deal aligns with Aspire Pharma's mission to make a difference in the lives of patients through the delivery of an enhanced product portfolio, which Aspire Pharma Chief Executive, Richard Condon, sees further enhancing the business’ growth trajectory.  

Mr Condon said: “We are pleased to announce our latest acquisition, a strategic move that not only strengthens our portfolio but also supports our central mission to meet patient needs, in terms of enhancing supply and access to essential, affordable, medicines.

“By integrating these important products into our existing portfolio, we are reaffirming our commitment to supporting patient care by offering true value to the NHS, payors and healthcare professionals.”

Under the deal, Aspire Pharma will gain the transfer of existing inventory, as well as the UK distribution rights for the products.

About Aspire Pharma

Aspire was established with a simple mission: To make a difference to the lives of patients through the development and supply of innovative products and medicines throughout the world. Aspire is present in the specialty, niche generics, branded generics, and medical device sectors. Aspire was majority acquired by an affiliate of H.I.G. Capital (“H.I.G.”) in 2021. For more information, go to: www.aspirepharma.com. 

About H.I.G. Capital

H.I.G. Capital is a leading global alternative investment firm with $67 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach. For more information, please refer to the H.I.G. website at hig.com.

*Based on total capital raised by H.I.G. Capital and affiliates.

Media Contact

Email: pressoffice@aspirepharma.com.

Tel: +44 1730 231148

10103472690 v 1.0 April 2025